期刊文献+

p53蛋白在三阴性乳腺癌组织中的表达及临床意义 被引量:2

The expression of p53 in triple-negative breast cancer and its clinical significance
下载PDF
导出
摘要 目的探讨p53蛋白在三阴性乳腺癌中的表达及其临床意义。方法回顾分析本院252例三阴性乳腺癌中资料完整的42例乳腺癌组织中p53蛋白的表达状态,分析其与三阴性乳腺癌患者临床病理特征及疾病进展时间的关系。结果42例乳腺癌组织中p53阳性表达率为52.38%(22/42),其表达与年龄、肿瘤大小、淋巴结转移、月经状态无关(P〉0.05)。p53阳性组中位疾病进展时间(TTP)为15个月(95%:8.3~21.7),P53阴性组中位TTP为21个月(95%:10.3~31.7),差异有统计学意义(P〈0.05)。结论p53阳性的三阴性乳腺癌患者的TTP明显低于p53阴性组,p53阳性可作为判断三阴性乳腺癌患者预后的一个重要指标。 Objective To investigate the expression of p53 in triple-negative breast cancer and its clinical significance. Methods The expression of p53 was examined immunohistochemically in tissue samples of 42 patients with informative triple-negative (ER, PR and Her-2 negative) breast cancer. Results The rate of positive p53 expression was 52.38% (22/42), which had no correlation with age, tumor size, axillary lymph node metastasis, and menstrual status (P〉0.05). Median time to progress (mTTP) in p53 positive group was 15 months (95% CI: 8.3-21.7 months), while that in p53 negative group was 21 months (95% CI: 10.3-31.7 months; P〈0.05). Conclusion P53 expression can be used as a prognostic indicator for patients with triple-negative breast cancer.
出处 《浙江医学》 CAS 2009年第5期570-572,共3页 Zhejiang Medical Journal
关键词 P53 三阴性乳腺癌 TTP p53 triple-negative breast cancer TTP
  • 相关文献

参考文献15

  • 1Anders C,Carey L A.Understanding and treating triple-negative breast cancer[J].Oncology(Williston Park),2008,22(11):1233-1239.
  • 2Shiu K K,Tan D S,Reis-Filho J S.Development of therapeutic approaches to 'triple negative' phenotype breast cancer[J].Expert Opin Ther Targets,2008,12(9):1123-1137.
  • 3李海志,张炜明,易彤波,武正炎.三阴性乳腺癌的临床病理特征及与CK19表达的相关性研究[J].内分泌外科杂志,2008,2(2):79-82. 被引量:6
  • 4王晓稼,Kevin R.Fox.受体三阴性乳腺癌的分子特征与治疗研究进展[J].癌症进展,2008,6(2):129-134. 被引量:4
  • 5李海志,武正炎.三阴性乳腺癌[J].内分泌外科杂志,2008,2(3):198-201. 被引量:8
  • 6Conlin A K,Seidman A D.Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative,hormone-insensitive metastatic breast cancer:current status and future opportunities[J].Clin Breast Cancer,2008,8(3):215-223.
  • 7Silva O,Lopes G,Morgenzstern D,et al.A Phase II trial of split,low-dose docetaxel and low-dose capecitabine:a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer[J].Clin Breast Cancer,2008,8(2):162-167.
  • 8Razzak A R,Lin N U,Winer E P.Heterogeneity of breast cancer and implications of adjuvant chemotherapy[J].Breast Cancer,2008,15(1):31-34.
  • 9Bottini A,Dogliot ti L,Bersiga A,et al.p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with ant-hracycline-containing regimens[J].Ann Oncol,2003,14(7):1156.
  • 10Askmalm M S,Carstensen J,Nordenskj?ld B,et al.Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients[J].Acta Oncol,2004,43(3):235-244.

二级参考文献43

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量:126
  • 2阮永威,金星,马宏岩.乳腺癌p53,ki-67和bcl-2的表达与新辅助化疗的关系[J].中国普通外科杂志,2006,15(4):247-249. 被引量:9
  • 3[1]Nielsen TO,Hsu FD,Jensen K,et al.Immunohistocbemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res,2004,10(16):5367
  • 4[2]Cleator S,Heller W,Ccombes RC.Triple-negative breast cancer:Therapeutic options.Lancet Oncol,2007,8(3):235
  • 5[3]Paik S,Tang G,Shak S,et al.Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer.Cancer J Clin Oncol,2006,24(23):3726
  • 6[4]Cronin M,Sangli C,Liu ML,et al.Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative,estrogen receptor-positive breast Cancer.Clin Chem,2007,53(6):1084
  • 7[5]Scrlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc Natl Acad Sci USA.2001,98(19):10869
  • 8[6]Abd El-Rehim DM,Pinder SE,Paish CE,et al.Expression of luminal and basal eytokeratina in human breast carcinoma.J Pathol,2004,203(2):661
  • 9[7]van de Rijn M,Perou CM,Tibshirani R,Haas P,Kallioniemi O.Kononen J,et al.Expression of cytokeratins 17 and 5 identifes.a group of breast carcinomas with poor clinical outcome.Am J Pathol,2002,161(6):1991
  • 10[8]Liedtke C,Mazouni C,Hess KR,et al.Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer.J Clin Oncol,2007(ASCO Annual Meeting),25(18S,Part Ⅰ):A10519

共引文献18

同被引文献33

  • 1周旭,易继林,郭悦青,刘恩宇,李兴睿.PTEN与hTERT在肝细胞肝癌中的表达及其相关性研究[J].中华实验外科杂志,2005,22(1):55-57. 被引量:17
  • 2陈庆永,陈剑英,陈道达,吴河水.抑癌基因PTEN在乳腺浸润性导管癌中的表达及临床意义[J].临床外科杂志,2005,13(5):280-281. 被引量:5
  • 3张宏艳,宋三泰,江泽飞,郑晓玲,黄焰,李刚.乳腺癌组织中PTEN的表达及其临床意义[J].解放军医学杂志,2006,31(10):963-965. 被引量:7
  • 4葛成华,王世伟,曾和平,陈晔,周海茵,汤旻,叶古祥.腹腔镜在不明原因急腹症中的应用[J].腹腔镜外科杂志,2007,12(2):141-142. 被引量:16
  • 5Liauw JJ, Cheah WK. Laparoscopic management of acute small bowel obstruction[ J]. Asian J Surg ,2005,28 ( 3 ) : 185 - 188.
  • 6Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EG- FR-targeted therapies[ J]. Breast,2007,16( 1 ) :104 - 107.
  • 7Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer clinical features and patterns of recurrence [ J ]. Clin Cancer Res 2007,13 ( 15 Pt 1 ) :4429 - 4434.
  • 8Chattopadhyay S, Zhao R, Krupenko SA, et al. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line[ J]. Mol Cancer Ther,2006,5 (2) :438 -449.
  • 9Janne PA, Simon GR, Langer C J, et al. Phase Ⅱ trial of pemetrexed and gemeitabine in chemotherapy-naive malignant pleural mesothelio- ma[ J ]. J Clin Oncol,2008,26 ( 9 ) : 1465 - 1471.
  • 10Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelio- ma:results of an International Expanded Access Program [ J ], J Thorac Oncol,2008,3 (7) :764 -771.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部